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Abstract
Background: Achievement of the UNAIDS 90-90-90 targets in Sub-Sahara Africa is challenged by a weak care-cascade
with poor linkage to care and retention in care. Community-based HIV testing and counselling (HTC) is widely used in
African countries. However, rates of linkage to care and initiation of antiretroviral therapy (ART) in individuals who
tested HIV-positive are often very low. A frequently cited reason for non-linkage to care is the time-consuming
pre-ART assessment often requiring several clinic visits before ART-initiation.
Methods: This two-armed open-label randomized controlled trial compares in individuals tested HIV-positive
during community-based HTC the proposition of same-day community-based ART-initiation to the standard of
care pre-ART assessment at the clinic. Home-based HTC campaigns will be conducted in catchment areas of six
clinics in rural Lesotho. Households where at least one individual tested HIV positive will be randomized. In the
standard of care group individuals receive post-test counselling and referral to the nearest clinic for pre-ART
assessment and counselling. Once they have started ART the follow-up schedule foresees monthly clinic visits.
Individuals randomized to the intervention group receive on the spot point-of-care pre-ART assessment and
adherence counselling with the proposition to start ART that same day. Once they have started ART, follow-up
clinic visits will be less frequent. First primary outcome is linkage to care (individual presents at the clinic at
least once within 3 months after the HIV test). The second primary outcome is viral suppression 12 months
after enrolment in the study. We plan to enrol a minimum of 260 households with 1:1 allocation and parallel
assignment into both arms.
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Discussion: This trial will show if in individuals tested HIV-positive during community-based HTC campaigns the
proposition of same-day ART initiation in the community, combined with less frequent follow-up visits at the clinic
could be a pragmatic approach to improve the care cascade in similar settings.
Trial registration: NCT02692027, registered February 21, 2016
Keywords: Linkage to care, Retention in care, Viral suppression, HIV, Antiretroviral therapy, Lesotho, Africa, Randomized
controlled trial, Care cascade
Background
In November 2014 the Joint United Nations Programme
on HIV/AIDS (UNAIDS) published the 90-90-90 targets
for 2020 [1]. The strategy aims at a massive scale-up in
coverage of antiretroviral therapy (ART) among individ-
uals infected with HIV. Based on accumulated evidence
that viral suppression through successful ART re-
duces the risk of transmission [2, 3], it is expected
that – if achieved – the 90-90-90 targets would lead
to a reduction of the yearly global HIV-incidence
from 2 million currently to 500,000 by 2020 [4]. In
2015 two randomized controlled trials showed the
benefit of starting ART as early as possible for in-
fected individuals – even if CD4-cell counts were
above the threshold of 500 cells/mL [5, 6], leading
the World Health Organization (WHO) to recom-
mend that anyone infected with HIV should start
ART as soon as possible after diagnosis [7]. A “seek-test-
treat” strategy bears, however, unprecedented challenges
in settings where HIV is hyperendemic and resources may
be limited [8, 9].
The Continuum of Care Cascade (“the cascade”) in-
volves the steps HIV-infected individuals have to take
in order to achieve viral suppression. It starts with
knowing one’s HIV status, continues with linkage to
care after a positive HIV test, initiation of ART, un-
interrupted continuation of ART (retention in care
and adherence to medication), and ends with sus-
tained viral suppression [10]. Already prior to an-
nouncement of the “seek-test-and-treat” approach,
weaknesses in the cascade often hampered the effect-
iveness of HIV programs in resource-rich as well as
resource-poor settings [11–13]. In Sub-Saharan Africa
the care cascade is still far from the 90-90-90 targets
with only 29 % of infected individuals estimated to be
on ART and virally suppressed in 2013 [1]. In order
to achieve the UNAIDS targets innovative, effective,
and practical approaches for improving the care cas-
cade are thus urgently needed [14, 15].
Linkage to care after an initial positive HIV test has
been described as the “Achilles’ heel” of the care cascade
[16]. Most studies from Sub-Saharan Africa report linkage
rates lower than 50 % [17–21]. In a cluster-randomized
trial comparing home-based with mobile-clinic HIV test-
ing and counselling (HTC) in Lesotho, only 25 % of newly
tested HIV-positive individuals accessed care within
1 month after the test [22].
Several interventions have been shown to improve
linkage to care, such as point-of-care CD4 count directly
after a positive HIV test [23], immediate start of cotri-
moxazole prophylaxis [24], incentives such as food-
assistance [25], extended post-test counselling during
home-visits, or community-workers accompaniment
[26–28]. However, controlled studies testing program-
matic intervention packages for improving linkage to
care are still largely lacking [29, 30]. Furthermore, it
must be noted that interventions, such as patient-
accompaniment or food support are resource inten-
sive and may work in small NGO-driven projects, but
are not sustainable on a larger scale [31]. In a sys-
tematic review addressing barriers for linkage to care,
transport cost and distance were the most frequently
cited factors for patients not enrolling in care after a
positive HIV test [32].
This paper describes the protocol of the CASCADE-trial.
This trial tests the effectiveness of same day home-based
ART initiation after a positive HIV test in combination
with a reduction of the frequency of follow-up visits to the
clinic as a pragmatic and programmatically feasible ap-




The CASCADE-trial is a two-armed open-label random-
ized controlled trial. Allocation is 1:1 with parallel assign-
ment. The intervention is targeted to individuals who
tested HIV-positive during community-based HTC and
entails same day community-based ART start combined
with less frequent follow-up visits. The intervention arm
will be compared to the standard of care in Lesotho (refer-
ral to facility for ART initiation followed by monthly
follow-up visits). The primary outcomes are linkage to
care at 3 months and viral suppression at 12 months after
a positive HIV test.
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Recruitment and participants
Participants will be recruited during community-based
HTC campaigns in the district of Butha-Buthe, in northern
Lesotho. Lesotho has an estimated adult HIV-prevalence of
23.4 %. Among the hyper-endemic countries of southern
Africa it has the highest transmission rate and the lowest
ART coverage [33]. Butha-Buthe is a rural district with an
estimated 110,000 habitants, mostly subsidence farmers or
mine workers, or construction or domestic workers in
neighboring South Africa. The district has only one small
town (Buthe-Buthe, ca. 25,000 habitants), the remaining
habitants live in villages scattered over a partly mountain-
ous surface of 1,767 km2. According to UNAIDS an esti-
mated 11,000 HIV-infected adult persons lived in the
district in 2013 [34].
Home-based HTC campaigns will be conducted for an
anticipated period of 3 months beginning at the end of
February in the catchment areas of six health care facil-
ities - four nurse-led health centers, one missionary and
one public hospital.
For rural areas, villages were randomly selected from a
list of eligible villages. A village is eligible if it is clearly
confined to the catchment area of one of the six facilities
and if it comprises between 40 and 80 households. In
Butha-Buthe town urban neighbourhoods were ran-
domly selected.
Three teams consisting of 4 lay counsellors, each super-
vised by one professional counsellor and a nurse visit all
households in selected villages and urban neighbourhoods
proposing HTC to all household members. Each house
will be visited once during the workweek. During this first
visit, lay counsellors enquire about absent household
members. If a household member is absent, the household
will be visited a second time during a weekend. The HTC-
coverage in visited areas will be assessed as part of a
nested study (see nested studies below).
If a household member tests HIV positive during the
HTC campaign, the study nurse is called to assess
whether the individual is eligible for the CASCADE trial.
Consenting individuals 18 years or older, living or work-
ing in the district of Butha-Buthe, having never been on
combination ART and willing to receive follow-up at
one of the six study facilities are eligible. Exclusion cri-
teria are: pregnant or breast-feeding, already enrolled in
care for another chronic disease, clinical WHO stage 4
or active tuberculosis, or a positive cryptococcal anti-
gen test.
If the sample size will not be reached during the
3 months of home-based HTC campaigns, the recruit-
ment period will be extended and mobile clinics will be
set up at urban or rural spots, such as taxi ranks or mar-
ket places. Procedures for home-based HTC as well as
HTC in mobile clinics in Lesotho has been described in
detail elsewhere [22].
Control and intervention arms
The control group follows the standard of care in Lesotho
[35, 36] that is similar to most settings in Sub Saharan
Africa. During the household visit, individuals found HIV-
positive and randomized to the control arm will receive
post-test counselling and a referral letter with an appoint-
ment at their chosen health facility. On the first visit to
the clinic, the participant receives a laboratory assessment
(CD4 cell-count, serum creatinine, haemoglobin) and a
first adherence counselling session. The participant must
then return to the clinic to receive his/her laboratory
results and to undergo a second adherence counselling
session. Depending on whether the participant is judged
as “ready to start ART” by the counsellor at the clinic,
he/she may start ART at their second clinic visit or
have to attend a third adherence counselling session.
Once the participant has started ART, the first and sec-
ond follow-up visits are scheduled for 14 and 28 days
after ART initiation, respectively. Thereafter, follow-up
visits are scheduled monthly until 6 months after ART
initiation. If the participant is clinically stable, clinical
follow-up visits may then be spaced to 3-monthly inter-
vals, but refills of ART must still be collected on a
monthly basis.
Participants randomized to the intervention group
receive post-test counselling and clinical and labora-
tory assessment with the possibility of same day ART
start combined with a reduced frequency of follow-up
visits. Directly after the positive HIV-test result the
study nurse assesses the participant clinically and per-
forms point-of-care laboratory testing (serum creatinine
(StatSensor Creat®, Nova® Biomedical), haemoglobin
(Hemocue®, HB301), and CD4 cell-count (PIMA Alere®)).
Thereafter, the participant receives a standardized
short adherence counselling. After adherence counsel-
ling, if – according to the nurse’s judgement - the
person understood the implications of lifelong ART,
he/she will be offered to start ART immediately.
Those who decide to start ART during the visit or in-
tend to start within 7 days will receive a 30-day ART-
supply and a follow-up appointment at the clinic
within 12 to 16 days. Choice of ART regimen and
use of cotrimoxazole prophylaxis follows national and
international guidelines [36, 37]. Participants with a
CD4 cell-count < 100 cells/mL will receive testing for
cryptococcal antigen. In case of a positive result, the
participant will be treated according to guidelines and
excluded from the study. In order to reduce travel
time and transport cost, participants who are clinic-
ally stable, will have their follow-up visits and ART
refills more widely spaced with appointments at
6 weeks, 3, 6, (9) and 12 months after ART initiation.
Participants are, however, encouraged to visit the
clinic at any time in case of problems or questions.
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Figure 1 summarizes flow of participants in the
study.
Primary outcomes
The trial has two primary outcomes. The first primary
outcome is linkage to care within 3 months after having
been tested HIV positive during the HTC-campaign. A
patient is considered to have linked to care if he/she
attends the clinic at least once within 90 days after en-
rolment in the trial. The second primary outcome is
viral suppression 12 months after enrolment in the trial.
Viral suppression is defined as a viral load (VL) <100
copies/mL between 11 and 14 months after diagnosis of
HIV-infection.
Secondary outcomes
Secondary outcomes are defined in Table 1.
Sample size and randomization
Households will be randomly allocated to a study arm at a
ratio of 1:1. A randomization list was generated by an inde-
pendent statistician with a block size of 4. Sealed and con-
secutively numbered envelopes containing treatment
assignment and study documents are provided to the study
nurses. It was not possible for treatment to be blinded.
The sample size for this trial is based on the primary
endpoint of linkage to care within 3 months after HIV
diagnosis. We expect 3-month linkage to care rates of
40 % in the control and 60 % in the intervention arm.
As the trial is randomized at the household level, we re-
quire a total of 260 households with at least one HIV-
positive participant to detect a 20 % increase in linkage
to care assuming a Type I error rate of 5 % and power of





Blood taken at first
clinic visit after the
positive HIV test result,
results communicated
at second clinic visit.
Performed in the
community the day
of the HIV test result
as point-of-care
Adherence-counselling At first and second
clinic visit
In the community,
directly after the HIV
test result
ART-initiation After at least two
adherence counselling
sessions at the clinic
Proposition of starting





Monthly 2 weeks – 6 weeks –
3–6–9–12 months
Table 1 Overview of services provided after a positive HIV test result during
community-based HTC campaigns in the control and intervention group
Fig. 1 CONSORT flow-chart of the CASCADE-trial. HTC: HIV testing and counselling; ART: anti-retroviral therapy
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90 %. With an estimated uptake of HTC of 94 %, a
prevalence of previously untreated HIV infection dur-
ing home-based HTC campaigns of 5 %, and a 10 %
trial participation refusal rate or choice of alternative
health facility, we need to visit 6200 households to achieve
the desired sample size of 260 households. In case more
than one HIV-positive individual is diagnosed in the
household, all individuals meeting eligibility criteria will
be included and randomized to the same arm. This will
only serve to increase the power of the study.
With the proposed sample size above, we will have suffi-
cient power to test the second primary endpoint of viral
suppression at 12 months. As those not linking to care will
be considered as failures, we expect viral suppression rates
of 25 % in the control arm and 45 % in the intervention
arm. With 130 individuals per arm, we will have 93 % power
to detect a difference of 20 % in viral suppression rates.
Analysis will be as intention to treat. The study will
be analysed using mixed effects logistic regression
models in order to account for the clustering of house-
holds (if sufficient number of households include more
than one HIV-positive individual in the study) and
village. If the arms are not found to be balanced on
important risk factors for linkage to care and viral sup-
pression, these risk factors will be adjusted for in
models. Linkage and viral suppression rates between
the control and intervention arm will be presented with
odds ratios and 95 % confidence intervals.
Subgroup analyses
Individuals working outside of Lesotho (primarily in
South Africa) are considered as a special subgroup as
they usually spend several months out of the country at
a time. This makes them an especially challenging
group to link to care, but once linked, they are typically
given refills and appointments every 3 months to ac-
commodate their work schedule. Rather than exclude
these individuals, we assume they will be evenly distrib-
uted among the treatment arms and they will be ana-
lysed in a separate subgroup analysis. As this group has
rarely been studied, we do not have valid estimates of
their expected linkage to care or viral suppression rates.
In addition, we do not expect to have the power to
sufficiently test for differences among these groups
but nevertheless find their results of great interest for
the design of future interventions targeting this
difficult-to-treat population.
Data collection and management
During the HTC-campaigns that serve as recruitment for
the CASCADE trial, lay counsellors, under the supervision
of a professional counsellor, will capture data on house-
holds visited and uptake and results of HTC using a tablet-
based app and platform (Visible Solutions AG, Switzerland,
visibleimpact.org). Data are stored in banking-standard ISO
27001 audited data centers. Aggregated data on number of
households visited and number of individuals tested are
regularly updated and publicly available on https://visible
impact.org/projects/1197-cascade-trial.
For individuals testing HIV-positive and participating
in the CASCADE-trial further documentation will be
done by study nurses on standardized paper-based forms.
These forms will be scanned in Lesotho and subsequently
Table 1 Secondary outcomes
Secondary outcome Definition Time-frame Remarks
ART-initiation Participant started ART 3 months after the enrolment
1-year retention in care Proportion confirmed dead (death record
at clinic or confirmed by a first-grade
relative), lost to follow-up (not attending
the clinic 11–14 months after HIV-test
and not confirmed dead), and retained
in care (on ART, attends the clinic)
12 months (11–14 months)
after enrolment
Participants with transfer out to
another clinic are excluded from
analysis. Participants are considered
as transferred out if the facility where
they were enrolled in care issued
a transfer letter.
Viral suppression under ART VL<100 copies/mL among those who
started ART
6 months (5–7) months) after
ART initiation
Change in body weight Delta between body weight (kg) at
baseline and 12 months after enrolment
At baseline and 12 months
(11–14 months) after enrolment
Change in CD4 cell count Delta between CD4 cell count (cells/mL)
at baseline and 12 months after enrolment
At baseline and 12 months
(11–14 months) after enrolment
Change in haemoglobin Delta haemoglobin (g/dL) at baseline and
12 months after enrolment
At baseline and 12 months
(11–14 months) after enrolment
New clinical WHO stage 3
or 4 events
Diagnosis of a new clinical WHO stage 3
or 4 event confirmed by study-physician
12 months (11–14 months) after
enrolment in the trial
WHO 3 or 4 events occurring within
3 months after ART-initiation and
judged as immune reconstitution
inflammatory syndrome by the study
physician will not be classified as
a new WHO stage 3 or 4 event
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processed with Data-Scan 5.7.7 (Neoptec, Montpellier,
France) for electronic data capture.
Storage of plasma
At recruitment and after 12 months of follow-up, plasma
samples of the trial participants will be stored at -80° at
the laboratory in Butha-Buthe hospital to allow retro-
spective resistance testing in case of treatment failure.
Ethics
The trial protocol has been approved by the Ethical Board
in Switzerland (Ethikkommission Nordwestschweiz;
EKNZ UBE 15/123) and the National Health Research
and Ethics Committee of the Ministry of Health of
Lesotho (89-2015). For the home-based HTC campaigns
the head of household or his/her substitute must pro-
vide written informed consent to the lay counsellor to
visit the household and to propose HTC to household
members who are present. As per Lesotho National
HTC guidelines each individual who agrees to HIV test-
ing must sign the National HTC Consent Form. In case
an individual is eligible for the CASCADE-trial he or
she will be asked for written informed consent. Individ-
uals who are not able to sign with their name can pro-
vide a thump-print.
Individuals who participate in nested study 2 as HIV-
negative controls sign a specific informed consent form
for blood draw and analysis of their lipid-status and gly-
cosylated haemoglobin (HbA1c) (see below for nested
study 2).
Individual participating in the CASCADE trial or
one of the nested studies will not receive any financial
compensation.
Trial status
Recruitment started with launch of the home-based HTC
campaigns on February 22, 2016. The status of recruitment
can be followed on https://visibleimpact.org/projects/1197-
cascade-trial/show/about. Recruitment is anticipated to fin-
ish by the end of May 2016. The recruitment phase may,
however, be extended if the targeted sample size is not
achieved. The trial is expected to be completed in
September 2017.
Nested studies
The trial hosts two nested studies. Nested study 1 is a
cross-sectional study assessing the testing coverage that
is achieved with two home-based HTC visits to the ran-
domly chosen areas for HTC-campaigns during recruit-
ment for the CASCADE-trial. Based on the number of
individuals tested and the total number of persons living
in the visited households of the testing areas, the HTC-
coverage after the first and second visit will be calcu-
lated. This study will provide information on feasibility
and resources needed to achieve the targeted 90 % HTC
coverage through home-based HTC when each area is
visited twice, once during the work week and once on a
weekend day, as described above.
Nested study 2 assesses lipid-profiles (total choles-
terol, LDL, HDL cholesterol, triglycerides) and glycosyl-
ated haemoglobin levels (HbA1c) among ART-naïve
HIV-infected individuals compared to non HIV-infected
controls. For the cohort of HIV-infected individuals who
initiate ART within the CASCADE-trial lipid-profiles and
HbA1c levels will again be assessed six and 12 months
after ART-initiation.
All eligible and consenting HIV-positive individuals in
the CASCADE trial (n = 260) will be included in the
sub-study. A target of 260 HIV negative controls will be
recruited from the same household as the HIV-positive
individuals. Only one HIV-negative individual will be se-
lected from each household with a preference for the
household member most closely matching the HIV-
positive individual in terms of gender and age. In case
there is no eligible HIV-negative individual in the same
household, the next eligible individual from the nearest
household will be enrolled.
Discussion
Community-based HTC campaigns will be one import-
ant intervention towards reaching the 90-90-90 goals as
it is a key strategy to access “hard-to-reach” populations
[38]. Despite recent popularity of home-based HTC
campaigns, linkage after a positive HIV test continues to
be uniformly poor in Sub Saharan Africa [16, 39] and in-
terventions improving linkage to and subsequent reten-
tion in care are greatly needed [40]. The combination of
interventions tested in the CASCADE-study could repre-
sent a feasible add-on to the current practice of health-
care-provider teams providing home-based HTC in rural
and urban areas. If proven to be effective, this strategy will
have the potential to be scaled up in similar settings with-
out large amounts of additional resources. A recently
conducted trial at a clinic in Johannesburg showed that
clinic-based fast-track initiation of ART results in bet-
ter linkage to care and higher viral suppression rates
after a positive HIV test result at a clinic [41]. To our
knowledge there are no trials assessing community-based
same-day ART-initiation.
The CASCADE-trial will be among the first randomized
controlled trials assessing community-based strategies to
reach the 90-90-90 targets in a resource-limited HIV
hyper-endemic setting. The trial has, however, several lim-
itations. It includes only adult individuals who are tested
during community-based HTC campaigns, thus excluding
individuals testing at facilities as well as children. More-
over, after enrolment, participants may decide to access
treatment outside the district of Butha-Buthe. This may
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lead to an underestimation of linkage to and retention in
care in both arms.
According to UNAIDS in 2013 only 45 % of individ-
uals were aware of their HIV-status, 39 % of diagnosed
individuals received ART and 29 % of infected individuals
had achieved viral suppression [1]. Implementation studies
testing feasible and pragmatic approaches for improving
the treatment cascade are urgently needed [14, 15]. The
CASCADE-trial, will add evidence for future implementa-
tion guidelines and policies in Lesotho and similar hyper-
endemic resource limited settings.
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